REAL-WORLD CLINICAL OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
Author(s)
Jiawen You, MD1, Yuanyuan Zhang, MD1, Yuan Meng, MD2, Yiming Zhao, MD1, Huiqing Huang, MD3, Wendong Chen, PhD, MD4, Jianbo Meng, PhD, MD1;
1Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting, CEO, Mississauga, ON, Canada
1Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting, CEO, Mississauga, ON, Canada
OBJECTIVES: This systematic literature review analyzed real-world evidence on autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (ndMM) in China.
METHODS: Following PRISMA guidelines, major English and Chinese databases were searched for observational studies published between 2015 and 2025 that included Chinese ndMM patients eligible for ASCT. Extracted data covered patient characteristics, treatment responses, and survival outcomes associated with ASCT and non-ASCT treatments. Single-arm meta-analysis with a random-effects model was used for evidence synthesis and pooled outcomes of the treatments for the same phase were compared using Cochran’s Q or chi-square tests.
RESULTS: A total of 88 observational studies (2015-2025) were included. Data were pooled using single-arm meta-analysis and the pooled outcomes for ASCT and non-ASCT treatments were compared using Cochran’s Q or chi-square tests. Compared to patients receiving non-ASCT treatments, ASCT recipients were younger (54.5 vs. 61.4 years), had more early-stage disease (ISS I: 25.8% vs. 15.1%), more t(11;14) (14.1% vs. 6.0%), and fewer complex karyotypes (2.9% vs. 31.7%). Plerixafor plus G-CSF significantly improved mobilization success over cyclophosphamide plus G-CSF (73.6% vs. 49.5%), though with slightly delayed engraftment. ASCT was associated with superior treatment response (CR: 78.5% vs. 45.3%; ≥VGPR: 98.6% vs. 75.0%) and higher 5-year overall survival rate (70.6% vs. 41.3%) and 5-year progression-free survival rate (41.3% vs. 18.0%). Advanced revised-ISS stage, IgD subtype, and suboptimal pre-ASCT response were associated with poorer survival prognosis in ASCT recipients.
CONCLUSIONS: Chinese ASCT recipients had more favorable baseline profiles and achieved significantly better clinical outcomes than those receiving non-ASCT treatments. Plerixafor-based mobilization enhanced stem cell collection success. However, advanced stage, IgD subtype, and inadequate pre-ASCT response could discount the effectiveness of ASCT.
METHODS: Following PRISMA guidelines, major English and Chinese databases were searched for observational studies published between 2015 and 2025 that included Chinese ndMM patients eligible for ASCT. Extracted data covered patient characteristics, treatment responses, and survival outcomes associated with ASCT and non-ASCT treatments. Single-arm meta-analysis with a random-effects model was used for evidence synthesis and pooled outcomes of the treatments for the same phase were compared using Cochran’s Q or chi-square tests.
RESULTS: A total of 88 observational studies (2015-2025) were included. Data were pooled using single-arm meta-analysis and the pooled outcomes for ASCT and non-ASCT treatments were compared using Cochran’s Q or chi-square tests. Compared to patients receiving non-ASCT treatments, ASCT recipients were younger (54.5 vs. 61.4 years), had more early-stage disease (ISS I: 25.8% vs. 15.1%), more t(11;14) (14.1% vs. 6.0%), and fewer complex karyotypes (2.9% vs. 31.7%). Plerixafor plus G-CSF significantly improved mobilization success over cyclophosphamide plus G-CSF (73.6% vs. 49.5%), though with slightly delayed engraftment. ASCT was associated with superior treatment response (CR: 78.5% vs. 45.3%; ≥VGPR: 98.6% vs. 75.0%) and higher 5-year overall survival rate (70.6% vs. 41.3%) and 5-year progression-free survival rate (41.3% vs. 18.0%). Advanced revised-ISS stage, IgD subtype, and suboptimal pre-ASCT response were associated with poorer survival prognosis in ASCT recipients.
CONCLUSIONS: Chinese ASCT recipients had more favorable baseline profiles and achieved significantly better clinical outcomes than those receiving non-ASCT treatments. Plerixafor-based mobilization enhanced stem cell collection success. However, advanced stage, IgD subtype, and inadequate pre-ASCT response could discount the effectiveness of ASCT.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO187
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
SDC: Oncology